Study S001022

A PHASE 3 STUDY TO EVALUATE THE SWITCH TO MONTHLY BEROBENATIDE FOR MAINTAINING WEIGHT IN ADULTS WHO ARE ON WEEKLY SEMAGLUTIDE OR TIRZEPATIDE (VESPER-SWITCH)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07845500
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 660
Start: 2026-10-01
Primary completion: 2028-02-16
Lead sponsor: Pfizer
Conditions: Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity
Interventions: DRUG:Semaglutide; DRUG:Tirzepatide; DRUG:Berobenatide
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Percent change from baseline in body weight [Baseline, Week 32]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.